Prolonged ENoxapariN in primarY Percutaneous Coronary Intervention; a Pilot Pharmacodynamic study (PENNY PCI study) - PENNY PCI Study

Dr0 个研究点目标入组 22 人开始时间: 2017年3月20日最近更新: 2019年2月28日

适应症

试验速览

暂无简介。

•1.Age = 18
•2.Confirmation of the diagnosis of STEMI by the clinical team on the basis of history, ECG changes and angiographic findings
•3.Pre-treatment with either ticagrelor or prasugrel
•4.Intention to proceed with PPCI
•5.Feasibility to obtain informed verbal consent pre PPCI
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 0
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 0

•1.Active bleeding that cannot be controlled by local measures
•2.Female patients of child bearing age who have not had a sterilisation procedure
•3.Patients with end stage renal failure requiring renal replacement therapy
•4.Known thrombocytopenia (Platelet count < 100,000/µL)
•5.Known history of intracranial haemorrhage
•6.Known current treatment with oral anticoagulants
•7.Known history of major surgery or trauma or history of GI/GU haemorrhage within the last month
•8.Known intracranial malignancy or aneurysm
•9.Known allergy to enoxaparin
•10.Inability to easily understand verbal information given in English for any reason
•11. Inability to give informed consent due to either temporary or permanent mental incapacity

发起方